Clinical Research in the Northwest

Why bother to participate in clinical trials and observational studies? Because, without participation we will never have new treatments for Huntington's.

Clinical Trials

Reach2HD
ongoing
(enrollment closed)

Reach2HD, an on-going clinical trial at Evergreen Neuroscience Center testing a new drug for Huntington’s disease is now closed for enrollment. Though the Northwest had a very short time period for enrolling participants, we had 6 accepted into the trial. Thank you to all participants, and to Evergreen for for it's clinical trial efforts for Huntington's disease.
CREST-E



READ MORE
For symptomatic HD individuals: This is a Phase 3 clinical trial that is testing whether high dose creatine can slow disease progression for those diagnosed with HD. Creatine is a nutritional supplement that has shown benefit in some HD mouse models. Potential benefit for individuals with HD has been suggested in earlier Phase 2 study (for safety and dosage testing) performed in Boston where decreased brain atrophy was shown for those individuals who took high dose creatine. This is a 3-year clinical trial. For full description visit www.hdtrials.org  or www.clinicaltrials.gov


Booth Gardner Parkinson's Care Center 
Dr. Pinky Agarwal,
Primary Investigator
Bari Dorward CCRC
Research Coordinator
12039 128th St., Suite 300,
Kirkland, WA 98034
Phone: 425.899.5370
Fax: 425.899.3147
Email: BJDorward@
evergreenhealthcare.org
 
2 CARE

This Clinical trial, which is testing the effect of high dose Co-Enzyme Q-10 on slowing progression of disease in symptomatic individuals is offered in Boise, Idaho


Idaho Elks Rehabilitation Hospital 
Lauren Seeburger,
Primary Investigator
Jane Harris,
Coordinator
Boise, ID
Phone: 208.489.4547
Email: jmharris@Elksrehab.org



Observational and Clinical Research Studies

Predict HD
(now enrolling)


READ MORE
The purpose of this study is to learn more about the diagnosis and progress of Huntington's Disease (HD). We are asking people over the age of 18 years, who have the gene for HD, but have not had an abnormal neurological examination, to take part in this study. We are also asking people who were at risk for HD but do not carry the gene (gene negative) to participate, for purposes of comparison. We will use paper-and-pencil tests, computer test, brain scans (MRI), blood and urine tests, and examinations by a doctor, to learn what happens as people move from health to HD.

University of Washington Department of Neurology
Dr. Ali Samii, MD,
Primary Investigator
Alma Macaraeg,
Research Coordinator
Phone: 206.543.3647
Fax: 206.685.8100
Email: almam@uw.edu 
ENROLL-HD
(now enrolling)

previously COHORT

READ MORE
Enroll-HD study is a new international study that involves North America, Europe, South America and parts of Asia. Data from those of you who have already contributed to COHORT (with your permission) will added to Enroll-HD.

This study is an active collaboration of HD patients, individuals born at risk for HD (regardless of whether they have been tested genetically), and their families. It requires about a half day visit once a year. This study is vital to the more rapid development of treatments for HD therapeutics and completion of clinical trials. Visit EnrollHD.org for more information and updates.

Transportation reimbursement available.  

Booth Gardner Parkinson’s Care Center (Evergreen Neuroscience Center)
Dr. Pinky Agarwal,
Primary Investigator
Marsha Merrick,
Coordinator
12039 NE 128th Street, Suite 300
Kirkland, WA 98034
Phone: 425-899-3115
Fax: 425-899-3147
Email: mgmerrick@
evergreenhealthcare.org
 



Previous Clinical Research Results

HART-ACR16
(closed)
This phase 2 trial has been completed and gave a positive signal of benefit for motor symptoms. A Phase 3 trial trial is planned for 2012.
Dimebon Phase 3
(closed)
Unfortunately this trial showed no benefit in Huntington’s or Alzheimer’s disease.



HDSA
NW Chapter Home
Helpline: 888-264-4372
Contact us:
- social worker
- join mailing list
- volunteer

READ MORE